TESTOSTERONE UNDECANOATE
| Brand name | KYZATREX |
|---|---|
| Active ingredient | TESTOSTERONE UNDECANOATE |
| Strength | 100MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2022 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 12403146 | March 2041 | product |
| 11617758 | March 2033 | product |
| 12357643 | March 2033 | product |
| 10576089 | December 2030 | product |
| 10576090 | December 2030 | product |
| 11590146 | December 2030 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.